Evidence map›Paper›PMID 35056467›Full record

ArticleMicroorganisms2021

Multiple Secondary Healthcare-Associated Infections Due to Carbapenem-Resistant Organisms in a Critically Ill COVID-19 Patient on Extensively Prolonged Venovenous Extracorporeal Membrane Oxygenation Support-A Case Report.

Hiroaki Baba, Hajime Kanamori, Issei Seike, Ikumi Niitsuma-Sugaya, Kentaro Takei, Kengo Oshima, Yudai Iwasaki, Yuko Ogata, Hirona Nishimaki, Daisuke Konno and 4 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Hiroaki BabaDepartment of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, 2-1 Seiryo machi, Aoba-ku, Sendai 980-8575, Japan.
Hajime KanamoriDepartment of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, 2-1 Seiryo machi, Aoba-ku, Sendai 980-8575, Japan.
Issei SeikeDepartment of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, 2-1 Seiryo machi, Aoba-ku, Sendai 980-8575, Japan.
Ikumi Niitsuma-SugayaDepartment of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, 2-1 Seiryo machi, Aoba-ku, Sendai 980-8575, Japan.
Kentaro TakeiDepartment of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, 2-1 Seiryo machi, Aoba-ku, Sendai 980-8575, Japan.
Kengo OshimaDepartment of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, 2-1 Seiryo machi, Aoba-ku, Sendai 980-8575, Japan.ORCID 0000-0003-4089-4910
Yudai IwasakiIntensive Care Unit, Tohoku University Hospital, 1-1 Seiryo machi, Aoba-ku, Sendai 980-8574, Japan.
Yuko OgataIntensive Care Unit, Tohoku University Hospital, 1-1 Seiryo machi, Aoba-ku, Sendai 980-8574, Japan.
Hirona NishimakiIntensive Care Unit, Tohoku University Hospital, 1-1 Seiryo machi, Aoba-ku, Sendai 980-8574, Japan.
Daisuke KonnoIntensive Care Unit, Tohoku University Hospital, 1-1 Seiryo machi, Aoba-ku, Sendai 980-8574, Japan.
Takuya ShigaIntensive Care Unit, Tohoku University Hospital, 1-1 Seiryo machi, Aoba-ku, Sendai 980-8574, Japan.ORCID 0000-0001-7303-3653
Koji SaitoIntensive Care Unit, Tohoku University Hospital, 1-1 Seiryo machi, Aoba-ku, Sendai 980-8574, Japan.
Koichi TokudaDepartment of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, 2-1 Seiryo machi, Aoba-ku, Sendai 980-8575, Japan.
Tetsuji AoyagiDepartment of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, 2-1 Seiryo machi, Aoba-ku, Sendai 980-8575, Japan.ORCID 0000-0001-6821-9701
Tohoku University · JPTohoku University Hospital · JP

Funding

Japan Society for the Promotion of Science JP18K16169
6 · The paper itself

Abstract

Patients with severe Coronavirus disease 2019 (COVID-19) are at high risk for secondary infection with multidrug-resistant organisms (MDROs). Secondary infections contribute to a more severe clinical course and longer intensive care unit (ICU) stays in patients with COVID-19. A man in his 60s was admitted to the ICU at a university hospital for severe COVID-19 pneumonia requiring mechanical ventilation. His respiratory condition worsened further due to persistent bacteremia caused by imipenem-non-susceptible

Indexed as

carbapenem-resistantcase reportCOVID-19extracorporeal membrane oxygenationhealthcare-associated infectionsintensive caremulti-resistant pathogens

Identifiers

PMID35056467
PMCPMC8781848
OpenAlexW4200587321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.